BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-597. [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020] [Cited by in Crossref: 318] [Cited by in F6Publishing: 297] [Article Influence: 18.7] [Reference Citation Analysis]
Number Citing Articles
1 Kaabia N, Ben Jazia E, Slim I, Fodha I, Hachfi W, Gaha R, Khalifa M, Hadj Kilani A, Trabelsi H, Abdelaziz A, Bahri F, Letaief A. Association of hepatitis C virus infection and diabetes in central Tunisia. World J Gastroenterol 2009; 15(22): 2778-2781 [PMID: 19522029 DOI: 10.3748/wjg.15.2778] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
2 Parise ER, Oliveira AC. [Insulin resistance in chronic hepatitits C]. Arq Gastroenterol. 2007;44:178-184. [PMID: 17962866 DOI: 10.1590/S0004-28032007000200017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24. [PMID: 20228847 DOI: 10.1038/onc.2010.36] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 16.7] [Reference Citation Analysis]
4 Wang C, Cheng P, Kao J. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [DOI: 10.1111/apt.15575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
5 Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL, Larson AM, Yeh MM, Camp DG, Smith RD. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology. 2007;46:649-657. [PMID: 17654742 DOI: 10.1002/hep.21751] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 6.1] [Reference Citation Analysis]
6 Durante-mangoni E, Zampino R, Ruggiero G, Adinolfi LE. Mild chronic hepatitis C with steatosis: Which treatment? Hepatology 2005;41:1198-1198. [DOI: 10.1002/hep.20670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World J Gastroenterol 2010; 16(10): 1171-1176 [PMID: 20222159 DOI: 10.3748/wjg.v16.i10.1171] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
8 Nascimento AC, Maia DR, Neto SM, Lima EM, Twycross M, Baquette RF, Lobato CM. Nonalcoholic Fatty liver disease in chronic hepatitis B and C patients from Western Amazon. Int J Hepatol 2012;2012:695950. [PMID: 22934189 DOI: 10.1155/2012/695950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Himoto T, Yoneyama H, Kurokohchi K, Mori H, Inukai M, Masugata H, Goda F, Haba R, Watanabe S, Senda S, Masaki T. Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C. J Clin Lab Anal 2012;26:342-8. [PMID: 23001979 DOI: 10.1002/jcla.21529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
10 Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JS. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C: . AIDS 2004;18:2221-34. [DOI: 10.1097/00002030-200411190-00002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
11 Halfon P, Pénaranda G, Carrat F, Bedossa P, Bourlière M, Ouzan D, Renou C, Tran A, Rosenthal E, Wartelle C, Delasalle P, Cacoub P. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Alimentary Pharmacology & Therapeutics 2009;30:61-70. [DOI: 10.1111/j.1365-2036.2009.03995.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
12 Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009;104:598-604. [PMID: 19262519 DOI: 10.1038/ajg.2008.125] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
13 Lin MS, Guo SE, Lin HS, Hsu JT, Lin YS, Lin TH, Huang TJ, Chen MY, Chung CM. Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study. Obes Facts 2016;9:101-11. [PMID: 27054361 DOI: 10.1159/000443692] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Lim CT, Kumar R. Hepatitis B and concomitant hepatic steatosis. Ann Transl Med 2017;5:38. [PMID: 28251117 DOI: 10.21037/atm.2016.12.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat. 2008;15:129-136. [PMID: 18184196 DOI: 10.1111/j.1365-2893.2007.00901.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
16 Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol 2017; 23(9): 1697-1711 [PMID: 28321170 DOI: 10.3748/wjg.v23.i9.1697] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
17 Carulli N. Metabolic syndrome - cardiovascular disease risk and more. Aliment Pharmacol Ther 2005;22:1-2. [DOI: 10.1111/j.1365-2036.2005.02586.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
18 Clausen LN, Lundbo LF, Benfield T. Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol 2014; 20(34): 12132-12143 [PMID: 25232248 DOI: 10.3748/wjg.v20.i34.12132] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
19 Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007; 13(4): 525-531 [PMID: 17278217 DOI: 10.3748/wjg.v13.i4.525] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 88] [Article Influence: 7.0] [Reference Citation Analysis]
20 Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. Infect Dis Clin North Am. 2006;20:115-135. [PMID: 16527652 DOI: 10.1016/j.idc.2006.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis. 2014;16:1-16. [PMID: 24372756 DOI: 10.1111/tid.12173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
22 Parra MD, de Morentin BEM, Martínez JA. Postprandial insulin response and mitochondrial oxidation in obese men nutritionally treated to lose weight. Eur J Clin Nutr 2005;59:334-40. [DOI: 10.1038/sj.ejcn.1602078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
23 Minakari M, Sameni FK, Shalmani HM, Molaee M, Zali MR. Hepatic steatosis in Iranian patients with chronic hepatitis C. Med Princ Pract 2008;17:126-30. [PMID: 18287796 DOI: 10.1159/000112966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol 2012; 18(3): 212-224 [PMID: 22294824 DOI: 10.3748/wjg.v18.i3.212] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
25 Aguilar M, Liu B, Holt EW, Bhuket T, Wong RJ. Impact of obesity and diabetes on waitlist survival, probability of liver transplantation and post-transplant survival among chronic hepatitis C virus patients. Liver Int 2016;36:1167-75. [DOI: 10.1111/liv.13091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
26 Clouston AD, Jonsson JR, Powell EE. Chronic hepatitis C and steatosis. Curr hepatitis rep 2004;3:123-8. [DOI: 10.1007/s11901-004-0021-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat. 2012;19:278-282. [PMID: 22404726 DOI: 10.1111/j.1365-2893.2011.01546.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
28 Amoras Eda S, Gomes ST, Freitas FB, Santana BB, Ishak G, de Araújo MT, Demachki S, da Silva Conde SR, de Oliveira Guimarães Ishak M, Ishak R, Vallinoto AC. NGF and P75NTR gene expression is associated with the hepatic fibrosis stage due to viral and non-viral causes. PLoS One 2015;10:e0121754. [PMID: 25816145 DOI: 10.1371/journal.pone.0121754] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
29 Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Takahashi S, Arihiro K, Chayama K. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases: CAP measurement for liver steatosis. Hepatol Res 2013;43:1182-9. [DOI: 10.1111/hepr.12094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
30 Zulet MA, Marti A, Parra MD, Martínez JA. Inflammation and conjugated linoleic acid: mechanisms of action and implications for human health. J Physiol Biochem 2005;61:483-94. [PMID: 16440602 DOI: 10.1007/BF03168454] [Cited by in Crossref: 42] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
31 El-Mesallamy HO, Hamdy NM, Rizk HH, El-Zayadi AR. Apelin serum level in Egyptian patients with chronic hepatitis C. Mediators Inflamm 2011;2011:703031. [PMID: 22007137 DOI: 10.1155/2011/703031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
32 Moslehi A, Hamidi-Zad Z. Role of SREBPs in Liver Diseases: A Mini-review. J Clin Transl Hepatol 2018;6:332-8. [PMID: 30271747 DOI: 10.14218/JCTH.2017.00061] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 10.7] [Reference Citation Analysis]
33 Ha M, Xia W, Tang D, Wu J, Sun L, Shen W, Huang Z, Chen X, Shan W. Hepatitis B e antigen-positive and high levels of alanine aminotransferase are associated with prevalence of metabolic syndrome in chronic HBV patients. Obes Res Clin Pract 2016;10:673-9. [PMID: 26515918 DOI: 10.1016/j.orcp.2015.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Himoto T, Hosomi N, Nakai S, Deguchi A, Kinekawa F, Matsuki M, Yachida M, Masaki T, Kurokochi K, Watanabe S. Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease. Scand J Gastroenterol. 2007;42:1078-1087. [PMID: 17710674 DOI: 10.1080/00365520701272409] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
35 Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113-118. [PMID: 15762194 DOI: 10.1530/eje.1.01821] [Cited by in Crossref: 173] [Cited by in F6Publishing: 169] [Article Influence: 10.8] [Reference Citation Analysis]
36 Koletzko L, Mahli A, Hellerbrand C. Development of an in vitro model to study hepatitis C virus effects on hepatocellular lipotoxicity and lipid metabolism. Pathol Res Pract 2018;214:1700-6. [PMID: 30201523 DOI: 10.1016/j.prp.2018.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol. 2005;17:447-455. [PMID: 15956842 DOI: 10.1097/01.bor.0000166386.62851.49] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 0.2] [Reference Citation Analysis]
38 Seidel N, Volkmann X, Länger F, Flemming P, Manns MP, Schulze-Osthoff K, Bantel H. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology. 2005;42:113-120. [PMID: 15920717 DOI: 10.1002/hep.20747] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
39 Kim E, Li K, Lieu C, Tong S, Kawai S, Fukutomi T, Zhou Y, Wands J, Li J. Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis. J Hepatol 2008;49:787-98. [PMID: 18809223 DOI: 10.1016/j.jhep.2008.06.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
40 Sirinawasatien A, Techasirioangkun T. The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:8814135. [PMID: 33204256 DOI: 10.1155/2020/8814135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther. 2009;7:293-308. [PMID: 19344243 DOI: 10.1586/eri.09.3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
42 Mena Á, Pedreira JD, Castro Á, López S, Vázquez P, Poveda E. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol. 2014;29:173-178. [PMID: 24219115 DOI: 10.1111/jgh.12432] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
43 Benini F, Pigozzi MG, Pozzi A, Bercich L, Reggiani A, Quattrocchi D, Distefano L, Donati P, Cesana BM, Lanzini A. Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. Dig Liver Dis. 2009;41:586-590. [PMID: 19131283 DOI: 10.1016/j.dld.2008.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
44 González-Reimers E, Quintero-Platt G, Rodríguez-Gaspar M, Alemán-Valls R, Pérez-Hernández O, Santolaria-Fernández F. Liver steatosis in hepatitis C patients. World J Hepatol 2015; 7(10): 1337-1346 [PMID: 26052379 DOI: 10.4254/wjh.v7.i10.1337] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
45 Kim NH, Cho YK, Kim BI, Kim HJ. Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment. Dig Dis Sci 2018;63:2792-9. [PMID: 29948568 DOI: 10.1007/s10620-018-5165-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
46 Manickam C, Wachtman L, Martinot AJ, Giavedoni LD, Reeves RK. Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus). PLoS One 2017;12:e0170240. [PMID: 28085952 DOI: 10.1371/journal.pone.0170240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
47 Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM. Studying hepatitis C virus: making the best of a bad virus. J Virol. 2007;81:8853-8867. [PMID: 17522203 DOI: 10.1128/jvi.00753-07] [Cited by in Crossref: 98] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
48 Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl. 2019;25:56-67. [PMID: 30609189 DOI: 10.1002/lt.25338] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
49 Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Manolakopoulos S, Manesis EK, Archimandritis AJ. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol. 2010;44:e87-e95. [PMID: 19881359 DOI: 10.1097/mcg.0b013e3181c0945a] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
50 Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00208-1. [PMID: 33618024 DOI: 10.1016/j.cgh.2021.02.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
51 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
52 Chung S, Keller JJ, Liang Y, Lin H. Association Between Viral Hepatitis and Erectile Dysfunction: A Population‐Based Case‐Control Analysis. The Journal of Sexual Medicine 2012;9:1295-302. [DOI: 10.1111/j.1743-6109.2012.02663.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
53 Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80-87. [PMID: 17187406 DOI: 10.1002/hep.21455] [Cited by in Crossref: 125] [Cited by in F6Publishing: 113] [Article Influence: 8.9] [Reference Citation Analysis]
54 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical Features of Hepatitis C Virus Carriers With Persistently normal Alanine Aminotransferase Levels. Hepat Mon 2012;12:77-84. [DOI: 10.5812/hepatmon.4851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Verdi H, Sare Koytak E, Önder O, Arslan Ergül A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu Ö, Bozkaya H. Peroxisome Proliferator-Activated Receptor α L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis: . Journal of Investigative Medicine 2005;53:353-9. [DOI: 10.2310/6650.2005.53706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
56 Liu M, Zhang SL, Cheng J, Liu Y, Wang L, Shao Q, Zhang J, Lin SM. Genes transactivated by hepatitis C virus core protein, a microarray assay. World J Gastroenterol 2005; 11(22): 3351-3356 [PMID: 15948238 DOI: 10.3748/wjg.v11.i22.3351] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
57 Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72-82. [PMID: 15920328 DOI: 10.1159/000084728] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
58 López-Prieto J, González-Reimers E, Alemán-Valls MR, de la Vega-Prieto MJ, Abreu-González P, Pelazas-González R, Hernández-Luis R, Jorge-Ripper C, Santolaria-Fernández F. Iron and proinflammatory cytokines in chronic hepatitis C virus infection. Biol Trace Elem Res 2013;155:5-10. [PMID: 23892696 DOI: 10.1007/s12011-013-9760-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
59 ElDeeb MK, Ghazal AA, Metwally DE, Elghlied LA. Possible roles of methylenetetrahydrofolate reductase polymorphism and folate status in patients with early hepatitis C virus genotype 4. Arab J Gastroenterol 2021;22:121-6. [PMID: 33664006 DOI: 10.1016/j.ajg.2020.12.001] [Reference Citation Analysis]
60 Grimm J, Peschel G, Müller M, Schacherer D, Wiest R, Weigand K, Buechler C. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J Clin Med 2021;10:1621. [PMID: 33920491 DOI: 10.3390/jcm10081621] [Reference Citation Analysis]
61 Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29 Suppl 2:13-25. [PMID: 19187069 DOI: 10.1111/j.1478-3231.2008.01952.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
62 Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. Clin Liver Dis. 2005;9:453-71, vii-viii. [PMID: 16023977 DOI: 10.1016/j.cld.2005.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
63 Voulgaris T, Sevastianos VA. Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus. Hepat Res Treat 2016;2016:7629318. [PMID: 26885388 DOI: 10.1155/2016/7629318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
64 Nakhjavani M, Mashayekh A, Khalilzadeh O, Asgarani F, Morteza A, Omidi M, Froutan H. Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011;35:111-6. [PMID: 21809486 DOI: 10.1016/j.clinre.2010.11.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
65 Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, Kao JH, Chen DS. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;43:235-42. [PMID: 15964656 DOI: 10.1016/j.jhep.2005.02.044] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 3.5] [Reference Citation Analysis]
66 Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028-1041. [PMID: 23262248 DOI: 10.1016/j.jhep.2012.12.014] [Cited by in Crossref: 104] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
67 Mirandola S, Bowman D, Hussain MM, Alberti A. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutr Metab (Lond) 2010;7:13. [PMID: 20178560 DOI: 10.1186/1743-7075-7-13] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
68 Adinolfi LE, Restivo L, Guerrera B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis. 2013;231:22-26. [PMID: 24125405 DOI: 10.1016/j.atherosclerosis.2013.08.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
69 Manickam C, Reeves RK. A mouse model for hepatitis C virus infection: are we there yet? Ann Infect 2017;1:5. [PMID: 30123888 DOI: 10.21037/aoi.2017.11.01] [Reference Citation Analysis]
70 Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496-502. [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 12.9] [Reference Citation Analysis]
71 Targher G, Lonardo A, Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest 2015;38:817-25. [DOI: 10.1007/s40618-015-0315-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
72 Petit JM, Minello A, Brisard C, Galland F, Duvillard L, Verges B, Hillon P. Plasma resistin concentration, and steatosis and insulin sensitivity in hepatitis C virus-infected patients. J Gastroenterol Hepatol 2006;21:624-624. [DOI: 10.1111/j.1440-1746.2006.04247.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
73 Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology. 2008;15:91-101. [PMID: 18602801 DOI: 10.1016/j.pathophys.2008.05.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
74 Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006;290:G847-G851. [PMID: 16603728 DOI: 10.1152/ajpgi.00522.2005] [Cited by in Crossref: 208] [Cited by in F6Publishing: 202] [Article Influence: 13.9] [Reference Citation Analysis]
75 Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016;17. [PMID: 27231906 DOI: 10.3390/ijms17060803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
76 Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: Does etiology make a difference? Journal of Hepatology 2006;44:190-6. [DOI: 10.1016/j.jhep.2005.06.018] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 6.3] [Reference Citation Analysis]
77 Ray SC, Thomas DL. Hepatitis C. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2157-85. [DOI: 10.1016/b978-0-443-06839-3.00154-5] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
78 Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42. [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014] [Cited by in Crossref: 395] [Cited by in F6Publishing: 366] [Article Influence: 26.3] [Reference Citation Analysis]
79 Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A, Cammà C. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 2009; 15(17): 2132-2138 [PMID: 19418586 DOI: 10.3748/wjg.15.2132] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
80 Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 2011;54:764-771. [PMID: 21618576 DOI: 10.1002/hep.24453] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
81 Tiftikci A, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, Ozdogan O, Celikel CA, Imeryuz N, Tozun N. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res. 2009;40:294-298. [PMID: 19608019 DOI: 10.1016/j.arcmed.2009.04.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
82 Pezacki JP, Sagan SM, Tonary AM, Rouleau Y, Bélanger S, Supekova L, Su AI. Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol 2009;9:2. [PMID: 19149867 DOI: 10.1186/1472-6769-9-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
83 Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655-1669. [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003] [Cited by in Crossref: 1758] [Cited by in F6Publishing: 1753] [Article Influence: 135.2] [Reference Citation Analysis]
84 Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A, Zavaroni I, Marchesini G. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 2008;31:146-52. [DOI: 10.1007/bf03345581] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
85 Aparcero López R, Campo JA, Romero-Gómez M. [Hepatitis C and metabolic syndrome]. Gastroenterol Hepatol 2010;33:530-40. [PMID: 20206412 DOI: 10.1016/j.gastrohep.2009.12.008] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol 2021; 27(17): 1959-1972 [PMID: 34007133 DOI: 10.3748/wjg.v27.i17.1959] [Reference Citation Analysis]
87 Lonardo A, Loria P, Bertolotti M, Carulli N. Statins and HCV: A complex issue. Hepatology 2007;45:257-257. [DOI: 10.1002/hep.21506] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
88 El Ray A, Asselah T, Moucari R, El Ghannam M, Taha AA, Saber MA, Akl M, Atta R, Shemis M, Radwan AS, Ghali A, Paradis V, Marcellin P. Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C. Eur J Gastroenterol Hepatol 2013;25:421-7. [PMID: 23470266 DOI: 10.1097/MEG.0b013e32835c9f69] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
89 Petit JM, Masson D, Minello A, Duvillard L, Galland F, Verges B, Gambert P, Hillon P. Lack of association between microsomal triglyceride transfer protein gene polymorphism and liver steatosis in HCV-infected patients. Molecular Genetics and Metabolism 2006;88:196-8. [DOI: 10.1016/j.ymgme.2005.12.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
90 Yuan F, Hou L, Wei L, Quan R, Wang J, Liu H, Liu J. Fowl Adenovirus Serotype 4 Induces Hepatic Steatosis via Activation of Liver X Receptor-α. J Virol 2021;95:e01938-20. [PMID: 33361420 DOI: 10.1128/JVI.01938-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Latif HA, Assal HS, Mahmoud M, Rasheed WI. Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus. Clin Exp Med 2011;11:123-9. [PMID: 20714777 DOI: 10.1007/s10238-010-0108-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
92 Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology. 2006;44:1648-1655. [PMID: 17133473 DOI: 10.1002/hep.21429] [Cited by in Crossref: 100] [Cited by in F6Publishing: 104] [Article Influence: 7.1] [Reference Citation Analysis]
93 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
94 Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol. 2012;47:834-844. [PMID: 22350701 DOI: 10.1007/s00535-012-0550-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
95 Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Huang HJ. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20:e3-10. [PMID: 23490387 DOI: 10.1111/jvh.12010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
96 Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology 2017;65:853-63. [PMID: 27981599 DOI: 10.1002/hep.28968] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
97 Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007;11:173-89, x. [PMID: 17544978 DOI: 10.1016/j.cld.2007.02.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
98 Lee M, Yang H, Wang C, Chen C. Response to Letter by Lin et al Regarding Article, “Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease”. Stroke 2011;42. [DOI: 10.1161/strokeaha.110.612291] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Wang FB, Zhu CL, Liu X, Gao GS. HBV inhibits apoB production via the suppression of MTP expression. Lipids Health Dis 2011;10:207. [PMID: 22074108 DOI: 10.1186/1476-511X-10-207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
100 Jiang L, Gu Y, Ye J, Liu F, Zhao Y, Wang C, Xu Y, Cao X, Zhang L, Dong W, Li F, Wang J, Wang H, Li Q. Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein. Biotechnol Lett 2012;34:2205-12. [PMID: 22941371 DOI: 10.1007/s10529-012-1034-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
101 Gigi E, Lagopoulos VI, Bekiari E. Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. World J Hepatol 2018; 10(9): 595-602 [PMID: 30310537 DOI: 10.4254/wjh.v10.i9.595] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
102 Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl. 2006;12:523-534. [PMID: 16555318 DOI: 10.1002/lt.20738] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 6.9] [Reference Citation Analysis]
103 Lemberg A, Schreier L, Romay S, Alejandra Fernández M, Rosello D, Gonzales S, Carlos Perazzo J, Julia Filinger E, Lujan Tomaro M. Involvement of serum apolipoprotein AI and B100 and lecithin cholesterol acyl transferase in alcoholic cirrhotics. Annals of Hepatology 2007;6:227-32. [DOI: 10.1016/s1665-2681(19)31903-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
104 Mitsuyoshi H, Itoh Y, Sumida Y, Minami M, Yasui K, Nakashima T, Okanoue T. Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Hepatol Res. 2008;38:348-353. [PMID: 18021228 DOI: 10.1111/j.1872-034x.2007.00280.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
105 Van Thiel DH, George M, Attar BM, Ramadori G, Ion-Nedelcu N. Plasma triglyceride levels may modulate hepatitis C viral replication. Dig Dis Sci 2014;59:881-5. [PMID: 24563239 DOI: 10.1007/s10620-014-3079-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Uraki S, Tameda M, Sugimoto K, Shiraki K, Takei Y, Nobori T, Ito M. Substitution in Amino Acid 70 of Hepatitis C Virus Core Protein Changes the Adipokine Profile via Toll-Like Receptor 2/4 Signaling. PLoS One 2015;10:e0131346. [PMID: 26121241 DOI: 10.1371/journal.pone.0131346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
107 Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. Int J Infect Dis. 2012;16:e436-e441. [PMID: 22486858 DOI: 10.1016/j.ijid.2012.02.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
108 Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxì A. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol. 2009;15:2132-2138. [PMID: 19418586 DOI: 10.3748/wjg.15.2132.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D’Antò M, Capasso R, Zappia V, Ruggiero G. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology. 2005;41:995-1003. [PMID: 15834927 DOI: 10.1002/hep.20664] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 5.6] [Reference Citation Analysis]
110 Kaibori M, Ishizaki M, Matsui K, Nakatake R, Yoshiuchi S, Kimura Y, Kwon AH. Perioperative exercise for chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. Am J Surg. 2013;206:202-209. [PMID: 23374372 DOI: 10.1016/j.amjsurg.2012.07.035] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
111 Wang X, Chen HZ, Liu WT, Liu M, Zhou DQ, Chen Q, Peng B. The association of plasma high-density lipoprotein cholesterol levels and cirrhosis development in obese patients with chronic hepatitis B: a cohort study. Eur J Gastroenterol Hepatol 2021;33:738-44. [PMID: 33079778 DOI: 10.1097/MEG.0000000000001965] [Reference Citation Analysis]
112 de Chassey B, Navratil V, Tafforeau L, Hiet MS, Aublin-Gex A, Agaugué S, Meiffren G, Pradezynski F, Faria BF, Chantier T. Hepatitis C virus infection protein network. Mol Syst Biol. 2008;4:230. [PMID: 18985028 DOI: 10.1038/msb.2008.66] [Cited by in Crossref: 273] [Cited by in F6Publishing: 270] [Article Influence: 21.0] [Reference Citation Analysis]
113 Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, Sutti S, Marrone A, Ruggiero G, Albano E. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol. 2008;48:399-406. [PMID: 18164507 DOI: 10.1016/j.jhep.2007.10.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
114 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
115 Sulkowski MS. HAART and the HCV-infected liver: friend or foe? Journal of Hepatology 2004;41:181-4. [DOI: 10.1016/j.jhep.2004.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
116 Anty R, Gelsi E, Giudicelli J, Mariné-barjoan E, Gual P, Benzaken S, Saint-paul M, Sadoul JL, Huet PM, Tran A. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses: . European Journal of Gastroenterology & Hepatology 2007;19:671-7. [DOI: 10.1097/meg.0b013e3281532b9a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
117 Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 2011;305:123-43. [PMID: 21168955 DOI: 10.1016/j.canlet.2010.11.014] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.8] [Reference Citation Analysis]
118 Petit JM, Jooste V, Duvillard L, Minello A, Texier V, Galland F, Gambert P, Verges B, Hillon P. Apolipoprotein-AII concentrations are associated with liver steatosis in patients with chronic hepatitis C. Dig Dis Sci. 2007;52:3431-3434. [PMID: 17436096 DOI: 10.1007/s10620-006-9719-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
119 Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. Journal of Hepatology 2005;42:266-74. [DOI: 10.1016/j.jhep.2004.12.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
120 Hoare M, Das T, Alexander G. Ageing, telomeres, senescence, and liver injury. J Hepatol. 2010;53:950-961. [PMID: 20739078 DOI: 10.1016/j.jhep.2010.06.009] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 9.0] [Reference Citation Analysis]
121 Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver International 2010;30:554-9. [DOI: 10.1111/j.1478-3231.2009.02164.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
122 Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, Theocharis GJ, Labropoulou-Karatza C. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol. 2006;18:233-237. [PMID: 16462535 DOI: 10.1097/00042737-200603000-00002] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 5.7] [Reference Citation Analysis]
123 Machado MV, Oliveira AG, Cortez-pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors. Hepatology 2010;52:71-8. [DOI: 10.1002/hep.23619] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
124 Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol 2018; 24(11): 1269-1277 [PMID: 29568207 DOI: 10.3748/wjg.v24.i11.1269] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
125 Lo Iacono O, Venezia G, Petta S, Mineo C, De Lisi S, Di Marco V, Rodolico V, Amato M, Ferraro D, Giordano C. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;25:1181-1191. [PMID: 17451564 DOI: 10.1111/j.1365-2036.2007.03309.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
126 Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys. 2014;548:20-37. [PMID: 24631571 DOI: 10.1016/j.abb.2014.02.015] [Cited by in Crossref: 121] [Cited by in F6Publishing: 113] [Article Influence: 17.3] [Reference Citation Analysis]
127 Ahn H, Kim DW, Ko Y, Ha J, Shin YB, Lee J, Sung YS, Kim KW. Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: A new paradigm beyond sarcopenia. Ageing Res Rev 2021;70:101398. [PMID: 34214642 DOI: 10.1016/j.arr.2021.101398] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Cheung O, Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis. 2008;12:573-585, viii-ix. [PMID: 18625429 DOI: 10.1016/j.cld.2008.03.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
129 Lonardo A, Ballestri S, Adinolfi LE, Violi E, Carulli L, Lombardini S, Scaglioni F, Ricchi M, Ruggiero G, Loria P. Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol. 2009;23:273-278. [PMID: 19373421 DOI: 10.1155/2009/369703] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
130 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800-806. [PMID: 32504663 DOI: 10.1016/j.jhep.2020.05.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
131 Bondini S, Kallman J, Wheeler A, Prakash S, Gramlich T, Jondle DM, Younossi ZM. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int. 2007;27:607-611. [PMID: 17498244 DOI: 10.1111/j.1478-3231.2007.01482.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
132 Grima PF, Chiavaroli R, Grima P. Ultrasonographic assessment of lipodystrophy in HIV-1-infected patients. Radiol Med 2009;114:141-51. [PMID: 18956151 DOI: 10.1007/s11547-008-0333-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
133 Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221-1228. [PMID: 17689296 DOI: 10.1016/j.cgh.2007.05.020] [Cited by in Crossref: 314] [Cited by in F6Publishing: 284] [Article Influence: 22.4] [Reference Citation Analysis]
134 Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Ginés P. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006;169:2042-2053. [PMID: 17148667 DOI: 10.2353/ajpath] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
135 Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World J Gastroenterol 2014; 20(23): 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
136 Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, Inuzuka T, Mizuguchi A, Shimizu K, Hatano E, Uemoto S, Chiba T, Marusawa H. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology 2014;146:222-32.e35. [PMID: 24055508 DOI: 10.1053/j.gastro.2013.09.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
137 Torres DM, Harrison SA. Hepatitis C, insulin resistance, and steatosis. Curr hepatitis rep 2007;6:129-37. [DOI: 10.1007/s11901-007-0015-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
138 Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005;22 Suppl 2:52-5. [PMID: 16225474 DOI: 10.1111/j.1365-2036.2005.02597.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
139 Feld JJ, Liang TJ. Hepatitis C — identifying patients with progressive liver injury. Hepatology 2006;43:S194-206. [DOI: 10.1002/hep.21065] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 4.2] [Reference Citation Analysis]
140 Ogawa E, Takayama K, Hiramine S, Hayashi T, Toyoda K. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Aliment Pharmacol Ther 2020;52:866-76. [DOI: 10.1111/apt.15976] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
141 Oliveira AC, Parise ER, Catarino RM, Lanzoni V, Leite-Mor MM, Simon KA, Junqueira VB. Insulin resistance and not steatosis is associated with modifications in oxidative stress markers in chronic hepatitis C, non-3 genotype. Free Radic Res 2009;43:1187-94. [PMID: 19905981 DOI: 10.3109/10715760903247249] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
142 Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat. 2006;13:73-80. [PMID: 16436124 DOI: 10.1111/j.1365-2893.2005.00669.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 7.3] [Reference Citation Analysis]
143 Kim AY, Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology. 2009;137:795-814. [PMID: 19549523 DOI: 10.1053/j.gastro.2009.06.040] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 10.4] [Reference Citation Analysis]
144 Lonardo A, Targher G. NAFLD: Is There Anything New under the Sun? Int J Mol Sci 2017;18:E1955. [PMID: 28895919 DOI: 10.3390/ijms18091955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
145 Jafarian A, Ebrahimi A, Azmoudeh Ardalan F, Dashti H, Rahimi M, Salehi M, Nasiri Toosi M. NAFLD Prevalence in a Young Cadaveric Organ Donor Population. Hepat Mon 2014;14:e21574. [PMID: 25419218 DOI: 10.5812/hepatmon.21574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Younossi ZM. Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. J Gastroenterol Hepatol 2004;19:S253-7. [DOI: 10.1111/j.1440-1746.2004.03682.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
147 Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645. [PMID: 23956991 DOI: 10.1155/2013/564645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
148 Kumar R. Hard clinical outcomes in patients with NAFLD. Hepatol Int 2013;7 Suppl 2:790-9. [PMID: 26202293 DOI: 10.1007/s12072-013-9455-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
149 Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F, Ferrannini E, Loguercio C, Lonardo A, Marra F, Mancini M, Miele L, Nobili V, Baroni GS, Alessandro F, Ballestri S, Rossana Brunetto M, Coco B, Grieco A, Fargion S, Kondili L, Nascimbeni F, Prinster A, Romagnoli D, Taddei S, Vanni E, Vella S. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease 2016;48:333-42. [DOI: 10.1016/j.dld.2015.10.027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
150 Younossi Z, Kochems K, de Ridder M, Curran D, Bunge EM, de Moerlooze L. Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. Hum Vaccin Immunother 2017;13:2695-706. [PMID: 28742983 DOI: 10.1080/21645515.2017.1353850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
151 Adinolfi LE, Restivo L, Marrone A. The predictive value of steatosis in hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2013;7:205-213. [PMID: 23445230 DOI: 10.1586/egh.13.7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
152 McPherson S, Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol 2008;49:1046-54. [PMID: 18752865 DOI: 10.1016/j.jhep.2008.06.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
153 Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications. 2006;20:113-120. [PMID: 16504840 DOI: 10.1016/j.jdiacomp.2006.01.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
154 Abdalla MY, Mathahs MM, Ahmad IM. Reduced heme oxygenase-1 expression in steatotic livers infected with hepatitis C virus. Eur J Intern Med. 2012;23:649-655. [PMID: 22939811 DOI: 10.1016/j.ejim.2012.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
155 Ferrara M, Umlauf A, Sanders C, Meyer JM, Allen McCutchan J, Duarte N, Hampton Atkinson J, Grant I, Ellis RJ; CHARTER Group. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res 2014;218:201-8. [PMID: 24794030 DOI: 10.1016/j.psychres.2014.04.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
156 Siqueira ER, Oliveira CP, Muniz MT, Silva F, Pereira LM, Carrilho FJ. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the Northeast of Brazil. Nutr J 2011;10:86. [PMID: 21854603 DOI: 10.1186/1475-2891-10-86] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
157 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother. 2011;12:2215-2234. [PMID: 21883025 DOI: 10.1517/14656566.2011.597742] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
158 Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007;46:1126-1132. [PMID: 17335930 DOI: 10.1016/j.jhep.2007.01.021] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 7.8] [Reference Citation Analysis]
159 Napolitano M, Giuliani A, Alonzi T, Mancone C, D’Offizi G, Tripodi M, Bravo E. Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C infection induce altered cellular lipid metabolism. J Med Virol. 2007;79:254-258. [PMID: 17245726 DOI: 10.1002/jmv.20793] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
160 Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-8. [PMID: 28052632 DOI: 10.1111/liv.13282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
161 Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662-669. [PMID: 18666246 DOI: 10.1002/hep.22402] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 6.5] [Reference Citation Analysis]
162 Sato C, Saito T, Misawa K, Katsumi T, Tomita K, Ishii R, Haga H, Okumoto K, Nishise Y, Watanabe H. Impaired mitochondrial β-oxidation in patients with chronic hepatitis C: relation with viral load and insulin resistance. BMC Gastroenterol. 2013;13:112. [PMID: 23841691 DOI: 10.1186/1471-230x-13-112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
163 Vespasiani-Gentilucci U, Gallo P, Vincentis AD, Galati G, Picardi A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol 2014; 20(11): 2825-2838 [PMID: 24659875 DOI: 10.3748/wjg.v20.i11.2825] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
164 Moon J, Kallman J, Winter P, Srishord M, Fang Y, Gerber L, Younossi Z. Disparities in Activity Level and Nutrition Between Patients With Chronic Hepatitis C and Blood Donors. PM&R 2012;4:436-41. [DOI: 10.1016/j.pmrj.2012.02.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
165 Romero-gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-de-rueda P, López-serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41. [DOI: 10.1053/j.gastro.2004.12.049] [Cited by in Crossref: 536] [Cited by in F6Publishing: 480] [Article Influence: 33.5] [Reference Citation Analysis]
166 Zampino R, Marrone A, Rinaldi L, Guerrera B, Nevola R, Boemio A, Iuliano N, Giordano M, Passariello N, Sasso FC. Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. Infection. 2018;. [PMID: 30066228 DOI: 10.1007/s15010-018-1185-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
167 Ripoli M, Pazienza V. Impact of HCV genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 2011;9:747-59. [PMID: 21905784 DOI: 10.1586/eri.11.94] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
168 Talal AH, Ding Y, Venuto CS, Chakan LM, McLeod A, Dharia A, Morse GD, Brown LS, Markatou M, Kharasch ED. Toward precision prescribing for methadone: Determinants of methadone deposition. PLoS One 2020;15:e0231467. [PMID: 32302325 DOI: 10.1371/journal.pone.0231467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
169 Arendt BM, Mohammed SS, Aghdassi E, Prayitno NR, Ma DW, Nguyen A, Guindi M, Sherman M, Heathcote EJ, Allard JP. Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr 2009;139:691-5. [PMID: 19211827 DOI: 10.3945/jn.108.101782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
170 Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, Zhang H, Gao Y, Mao Y, Zhao J. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0131664. [PMID: 26121037 DOI: 10.1371/journal.pone.0131664] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
171 Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, Farci P, O'Brien CB, Lardelli P, Blotner S. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol. 2006;44:679-685. [PMID: 16487620 DOI: 10.1016/j.jhep.2006.01.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
172 Minakari M, Molaei M, Shalmani HM, Alizadeh AHM, Jazi AHD, Naderi N, Shavakhi A, Mashayekhi R, Zali MR. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors: . European Journal of Gastroenterology & Hepatology 2009;21:512-6. [DOI: 10.1097/meg.0b013e328326792e] [Cited by in Crossref: 42] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
173 Sumida Y, Kanemasa K, Hara T, Inada Y, Sakai K, Imai S, Yoshida N, Yasui K, Itoh Y, Okanoue T, Yoshikawa T. Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. J Gastroenterol Hepatol 2011;26:836-42. [PMID: 21054524 DOI: 10.1111/j.1440-1746.2010.06568.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
174 Martin C, Nielsen SU, Ibrahim S, Bassendine MF, Toms GL. Binding of liver derived, low density hepatitis C virus to human hepatoma cells. J Med Virol. 2008;80:816-823. [PMID: 18360895 DOI: 10.1002/jmv.21150] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
175 Elgouhari HM, Conjeevaram HS. Impact of obesity, hepatic steatosis, and insulin resistance on hepatitis C treatment outcomes. Curr hepatitis rep 2008;7:127-33. [DOI: 10.1007/s11901-008-0026-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
176 Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med. 2008;3:99-108. [PMID: 18274709 DOI: 10.1007/s11739-008-0127-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
177 Mato JM, Lu SC. Homocysteine, the bad thiol. Hepatology. 2005;41:976-979. [PMID: 15841447 DOI: 10.1002/hep.20708] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
178 Ramos-casals M, Fornsb X, Sanchez-tapiasb J, Rodésb J. Chapter 16 Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection. Digestive Involvement in Systemic Autoimmune Diseases. Elsevier; 2008. pp. 209-304. [DOI: 10.1016/s1571-5078(07)00016-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 El-Zayadi A, Attia M, Barakat EM, Zalata K, Saeid A, Hamdy H, El-Nakeeb A. Non-alcoholic fatty liver disease in patients with HCV genotype 4. Gut 2007;56:1170-1. [PMID: 17356041 DOI: 10.1136/gut.2007.123331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
180 Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 2011;41:711-21. [PMID: 21682827 DOI: 10.1111/j.1872-034X.2011.00818.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
181 Ciccaglione AR, Marcantonio C, Tritarelli E, Equestre M, Vendittelli F, Costantino A, Geraci A, Rapicetta M. Activation of the ER stress gene gadd153 by hepatitis C virus sensitizes cells to oxidant injury. Virus Res. 2007;126:128-138. [PMID: 17368854 DOI: 10.1016/j.virusres.2007.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
182 Mehanna ET, Barakat BM, ElSayed MH, Tawfik MK. An optimized dose of raspberry ketones controls hyperlipidemia and insulin resistance in male obese rats: Effect on adipose tissue expression of adipocytokines and Aquaporin 7. Eur J Pharmacol 2018;832:81-9. [PMID: 29787773 DOI: 10.1016/j.ejphar.2018.05.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
183 Zampino R, Ingrosso D, Durante-Mangoni E, Capasso R, Tripodi MF, Restivo L, Zappia V, Ruggiero G, Adinolfi LE. Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat. 2008;15:740-746. [PMID: 18482281 DOI: 10.1111/j.1365-2893.2008.00994.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
184 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
185 Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, Verges B, Olsson NO, Gambert P, Hillon P. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240-2243. [PMID: 15644404 DOI: 10.1210/jc.2004-1266] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 4.4] [Reference Citation Analysis]
186 Liu RM. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal 2008;10:303-19. [PMID: 17979497 DOI: 10.1089/ars.2007.1903] [Cited by in Crossref: 99] [Cited by in F6Publishing: 97] [Article Influence: 7.6] [Reference Citation Analysis]
187 Lin C, Huang X, Liu H, Wang Y. Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Dig Dis Sci 2015;60:3513-24. [DOI: 10.1007/s10620-015-3772-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
188 Yi Z, Yuan Z. Hepatitis C Virus-Associated Cancers. Adv Exp Med Biol. 2017;1018:129-146. [PMID: 29052135 DOI: 10.1007/978-981-10-5765-6_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
189 Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006;49:450-465. [PMID: 17064291 DOI: 10.1111/j.1365-2559.2006.02416.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 168] [Article Influence: 12.0] [Reference Citation Analysis]
190 Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol. 2005;100:711-715. [PMID: 15743372 DOI: 10.1111/j.1572-0241.2005.40898.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
191 Mousa N, Gad Y, Abdel-Aziz A, Abd-Elaal I. Increased α-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4. Int J Hepatol 2012;2012:636392. [PMID: 22675639 DOI: 10.1155/2012/636392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
192 Guidi M, Muratori P, Granito A, Muratori L, Pappas G, Lenzi M, Bianchi FB. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther. 2005;22:943-949. [PMID: 16268968 DOI: 10.1111/j.1365-2036.2005.02679.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
193 Franceschini B, Russo C, Dioguardi N, Grizzi F. Increased liver mast cell recruitment in patients with chronic C virus-related hepatitis and histologically documented steatosis. J Viral Hepat 2007;14:549-55. [PMID: 17650288 DOI: 10.1111/j.1365-2893.2007.00859.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
194 Pavlidis C, Panoutsopoulos GI, Tiniakos D, Koutsounas S, Vlachogiannakos J, Zouboulis-Vafiadis I. Serum leptin and ghrelin in chronic hepatitis C patients with steatosis. World J Gastroenterol 2011; 17(46): 5097-5104 [PMID: 22171144 DOI: 10.3748/wjg.v17.i46.5097] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
195 Delgado-Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christofi M, Casson D, Cosimi AB, Chung RT. Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl. 2008;14:193-201. [PMID: 18236394 DOI: 10.1002/lt.21267] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
196 Chung WJ. [Chronic hepatitis C and insulin resistance]. Korean J Gastroenterol 2012;59:268-74. [PMID: 22544023 DOI: 10.4166/kjg.2012.59.4.268] [Reference Citation Analysis]
197 Machado MV, Cortez-pinto H. Insulin resistance and steatosis in chronic hepatitis C. Annals of Hepatology 2009;8:S67-75. [DOI: 10.1016/s1665-2681(19)31829-0] [Cited by in Crossref: 25] [Article Influence: 2.1] [Reference Citation Analysis]
198 Demir K, Akyuz F, Ozdil S, Aksoy N, Kaymakoglu S, Poturoglu S, Akyüz Ü, Besisik F, Boztas G, Mungan Z, Cevikbas U, Cakaloglu Y, Okten A. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Annals of Hepatology 2007;6:92-6. [DOI: 10.1016/s1665-2681(19)31938-6] [Cited by in Crossref: 14] [Article Influence: 1.0] [Reference Citation Analysis]
199 Koike K. Hepatitis C virus infection can present with metabolic disease by inducing insulin resistance. Intervirology. 2006;49:51-57. [PMID: 16166789 DOI: 10.1159/000087263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
200 Al-mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;44:463-9. [DOI: 10.1097/qai.0b013e318030ff8e] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
201 Livingstone S, Deubner H, Mcmahon B, Bruden D, Christensen C, Hennessy T, Bruce M, Sullivan D, Homan C, Williams J, Gretch D. Steatosis and hepatitis C in an Alaska Native/American Indian population. International Journal of Circumpolar Health 2016;65:253-60. [DOI: 10.3402/ijch.v65i3.18105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
202 Cobbold J, Morin S, Taylor-Robinson S. Transient elastography for the assessment of chronic liver disease: Ready for the clinic? World J Gastroenterol 2007; 13(36): 4791-4797 [PMID: 17828808 DOI: 10.3748/wjg.v13.i36.4791] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
203 Ratziu V, Heurtier A, Bonyhay L, Poynard T, Giral P. Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link. Aliment Pharmacol Ther. 2005;22 Suppl 2:56-60. [PMID: 16225475 DOI: 10.1111/j.1365-2036.2005.02598.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
204 Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Ginés P. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006;169:2042-2053. [PMID: 17148667 DOI: 10.2353/ajpath.2006.060081] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 7.6] [Reference Citation Analysis]
205 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
206 Afford SC, Adams DH. Following the TRAIL from hepatitis C virus and alcohol to fatty liver. Gut 2005;54:1518-20. [PMID: 16227354 DOI: 10.1136/gut.2005.067801] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
207 Persico M, Masarone M, La Mura V, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol 2009;15:462-6. [PMID: 19152451 DOI: 10.3748/wjg.15.462] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. Adv Ther 2016;33:291-319. [DOI: 10.1007/s12325-016-0306-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 10.6] [Reference Citation Analysis]
209 McLauchlan J. Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta 2009;1791:552-9. [PMID: 19167518 DOI: 10.1016/j.bbalip.2008.12.012] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
210 Blonsky JJ, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime. Aliment Pharmacol Ther 2008;27:855-65. [PMID: 18315584 DOI: 10.1111/j.1365-2036.2008.03672.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
211 Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, Ratziu V, Lonardo A. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014;232:99-109. [DOI: 10.1016/j.atherosclerosis.2013.10.030] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 11.1] [Reference Citation Analysis]
212 Riley P, O'Donohue J, Crook M. A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J Clin Pathol 2007;60:1384-91. [PMID: 17483247 DOI: 10.1136/jcp.2006.044891] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
213 Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, Minola E. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006;43:64-71. [PMID: 16374856 DOI: 10.1002/hep.20983] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 7.8] [Reference Citation Analysis]
214 González-Reimers E, López-Prieto J, Quintero-Platt G, Pelazas-González R, Alemán-Valls MR, Pérez-Hernández O, de-la-Vega-Prieto MJ, Gómez-Rodríguez MA, Martín-González C, Santolaria-Fernández F. Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis. World J Hepatol 2016; 8(1): 74-82 [PMID: 26783423 DOI: 10.4254/wjh.v8.i1.74] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
215 Cross TJS, Rashid MM, Berry PA, Harrison PM. The importance of steatosis in chronic hepatitis C infection and its management: A review. Hepatology Research 2010;40:237-47. [DOI: 10.1111/j.1872-034x.2010.00626.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
216 Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, Manesis EK. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006;13:303-310. [PMID: 16637860 DOI: 10.1111/j.1365-2893.2005.00677.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
217 Hanouneh IA, Feldstein AE, Lopez R, Yerian L, Pillai A, Zein CO, Zein NN. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008;6:584-589. [PMID: 18455698 DOI: 10.1016/j.cgh.2008.02.034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
218 Osama A, Ashour Y, Abd El-razek R, Monir D. Assessment of carotid intima-media thickness and carotid plaque formation among patients with ischemic stroke and hepatitis C virus infection. Egypt J Neurol Psychiatry Neurosurg 2019;55. [DOI: 10.1186/s41983-019-0054-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Kappel CR, Kretzmann NA, Alvares-da-Silva MR. IRS1 Expression in Hepatic Tissue and Leukocytes in Chronic Hepatitis C Virus Infected Patients: A Comparative Study. Int J Hepatol 2012;2012:698905. [PMID: 22830036 DOI: 10.1155/2012/698905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
220 Pineda-Tenor D, Gómez-Moreno AZ, Sánchez-Ruano JJ, Artaza-Varasa T, Virseda-Berdices A, Fernández-Rodríguez A, Mendoza PM, Jiménez-Sousa MÁ, Resino S. MTHFR rs1801133 Polymorphism Is Associated With Liver Fibrosis Progression in Chronic Hepatitis C: A Retrospective Study. Front Med (Lausanne) 2020;7:582666. [PMID: 33304912 DOI: 10.3389/fmed.2020.582666] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
221 Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009;16:492-499. [PMID: 19200134 DOI: 10.1111/j.1365-2893.2009.01098.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
222 Perrella A, Borgia G, Borrelli F, Di Sirio S, Gnarini M, Grattacaso S, Graf M, Guida M, Viola C, Guarnaccia M, Perrella O. TNF-alpha serum level elevations in chronic hepatitis C patients with diabetes mellitus. Int J Immunopathol Pharmacol 2005;18:189-93. [PMID: 15698524 DOI: 10.1177/039463200501800120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
223 Mindikoglu A, Regev A, Casanova-romero P, Bejarano P, Martinez E, Tzakis A, Schiff E. The Impact of Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome on Progression of Fibrosis in Patients With Recurrent HCV After Liver Transplantation. Transplantation Proceedings 2006;38:1440-4. [DOI: 10.1016/j.transproceed.2006.02.060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
224 Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22:64-70. [DOI: 10.1111/j.1365-2036.2005.02600.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
225 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 14.7] [Reference Citation Analysis]
226 Kuo YC, Chen IY, Chang SC, Wu SC, Hung TM, Lee PH, Shimotohno K, Chang MF. Hepatitis C virus NS5A protein enhances gluconeogenesis through upregulation of Akt-/JNK-PEPCK signalling pathways. Liver Int 2014;34:1358-68. [PMID: 25360475 DOI: 10.1111/liv.12389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
227 Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C. Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology 2007;5:245-54. [DOI: 10.1016/j.cgh.2006.11.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
228 Himoto T, Tani J, Miyoshi H, Yoneyama H, Mori H, Inukai M, Masugata H, Goda F, Senda S, Haba R, Masaki T. The ratio of insulin-like growth factor-I/insulin-like growth factor–binding protein-3 in sera of patients with hepatitis C virus–related chronic liver disease as a predictive marker of insulin resistance. Nutrition Research 2013;33:27-33. [DOI: 10.1016/j.nutres.2012.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
229 Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. 2006;24:1349-1357. [PMID: 17059516 DOI: 10.1111/j.1365-2036.2006.03114.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
230 Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 2006;26:1119-25. [DOI: 10.1111/j.1478-3231.2006.01347.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
231 Carulli L, Lonardo A, Lombardini S, Marchesini G, Loria P. Gender, fatty liver and GGT. Hepatology 2006;44:278-9. [PMID: 16799969 DOI: 10.1002/hep.21218] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
232 Clausen LN, Astvad K, Ladelund S, Larsen MV, Schønning K, Benfield T. Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. AIDS. 2012;26:1509-1516. [PMID: 22555162 DOI: 10.1097/qad.0b013e3283553581] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
233 Himoto T, Fujita K, Sakamoto T, Nomura T, Morishita A, Yoneyama H, Haba R, Masaki T. Clinical efficacy of free androgen index, a surrogate hallmark of circulating free testosterone level, in male patients with HCV-related chronic liver disease. J Clin Biochem Nutr 2018;63:238-45. [PMID: 30487676 DOI: 10.3164/jcbn.18-30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
234 Harrison SA. Liver Disease in Patients With Diabetes Mellitus. Journal of Clinical Gastroenterology 2006;40:68-76. [DOI: 10.1097/01.mcg.0000190774.91875.d2] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 8.3] [Reference Citation Analysis]
235 Himoto T, Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights. 2013;4:39-53. [PMID: 26000142 DOI: 10.1007/s13317-013-0046-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
236 Chapplain JM, Tattevin P, Guyader D, Begue JM, Beillot J, Turlin B, Souala F, Arvieux C, Rochcongar P, Michelet C. Mitochondrial abnormalities in patients with HIV-HCV co-infection as compared to patients with HCV mono-infection. HIV Clin Trials 2011;12:54-60. [PMID: 21388941 DOI: 10.1310/hct1201-54] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
237 Nordmann S, Vilotitch A, Roux P, Esterle L, Spire B, Marcellin F, Salmon-Ceron D, Dabis F, Chas J, Rey D, Wittkop L, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH). J Viral Hepat 2018;25:171-9. [PMID: 28984055 DOI: 10.1111/jvh.12797] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
238 Cuadros DF, Miller FD, Nagelkerke N, Abu-Raddad LJ. Association between HCV infection and diabetes type 2 in Egypt: is it time to split up? Ann Epidemiol. 2015;25:918-923. [PMID: 26499381 DOI: 10.1016/j.annepidem.2015.09.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
239 Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, D’Auria MV, Capasso R, Del Vecchio Blanco C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52:2387-2395. [PMID: 17410454 DOI: 10.1007/s10620-006-9703-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
240 Knobler H, Malnick S. Hepatitis C and insulin action: An intimate relationship. World J Hepatol 2016; 8(2): 131-138 [PMID: 26807209 DOI: 10.4254/wjh.v8.i2.131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
241 Adams LA, Angulo P, Abraham SC, Torgerson H, Brandhagen D. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int. 2006;26:298-304. [PMID: 16584391 DOI: 10.1111/j.1478-3231.2005.01238.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
242 Moucari R, Marcellin P, Asselah T. Stéatose au cours de l’hépatite chronique C : rôle de l’insulino-résistance et des facteurs viraux. Gastroentérologie Clinique et Biologique 2007;31:643-54. [DOI: 10.1016/s0399-8320(07)91911-9] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
243 Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008;82:2120-9. [PMID: 18077707 DOI: 10.1128/JVI.02053-07] [Cited by in Crossref: 339] [Cited by in F6Publishing: 215] [Article Influence: 24.2] [Reference Citation Analysis]
244 Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, Marcolongo M, Vario A, Datz C, Hussain MM, Alberti A. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology. 2006;130:1661-1669. [PMID: 16697730 DOI: 10.1053/j.gastro.2006.02.035] [Cited by in Crossref: 143] [Cited by in F6Publishing: 133] [Article Influence: 9.5] [Reference Citation Analysis]
245 Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5-13. [PMID: 15962320 DOI: 10.1002/hep.20750] [Cited by in Crossref: 250] [Cited by in F6Publishing: 243] [Article Influence: 15.6] [Reference Citation Analysis]
246 Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol. 2008;23:779-782. [PMID: 18028349 DOI: 10.1111/j.1440-1746.2007.05216.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
247 Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
248 Choi J. Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radic Biol Med. 2012;52:1135-1150. [PMID: 22306508 DOI: 10.1016/j.freeradbiomed.2012.01.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
249 Vidali M, Occhino G, Ivaldi A, Serino R, Moia S, Alchera E, Carini R, Rigamonti C, Sartori M, Albano E. Detection of auto-antibodies against cytochrome P4502E1 (CYP2E1) in chronic hepatitis C. Journal of Hepatology 2007;46:605-12. [DOI: 10.1016/j.jhep.2006.11.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
250 Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis. 2007;17:63-70. [PMID: 17164082 DOI: 10.1016/j.numecd.2006.08.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 67] [Article Influence: 6.1] [Reference Citation Analysis]
251 De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-dall'antonia F, Pazienza V, Pugnale P, Foti M, Hadengue A. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 2007;87:792-806. [DOI: 10.1038/labinvest.3700590] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
252 Sikorska K, Stalke P, Romanowski T, Rzepko R, Bielawski KP. Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C. Hepatobiliary Pancreat Dis Int 2013;12:377-84. [PMID: 23924495 DOI: 10.1016/s1499-3872(13)60059-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
253 Yoon EJ, Hu KQ. Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci 2006;3:53-6. [PMID: 16614743 DOI: 10.7150/ijms.3.53] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
254 Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33:86-98. [PMID: 28692197 DOI: 10.1111/jgh.13856] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 27.5] [Reference Citation Analysis]
255 Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines 2021;9:1491. [PMID: 34680608 DOI: 10.3390/biomedicines9101491] [Reference Citation Analysis]
256 Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N, Saksouk FA, Wheeler DE, Ehrinpreis MN. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. J Clin Gastroenterol. 2007;41:624-629. [PMID: 17577120 DOI: 10.1097/01.mcg.0000225680.45088.01] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
257 Hsieh YC, Lee KC, Su CW, Lan KH, Huo TI, Wang YJ, Huang HC, Lin HC, Chu CJ, Huang YH, Hou MC. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. J Chin Med Assoc 2021;84:472-7. [PMID: 33742989 DOI: 10.1097/JCMA.0000000000000517] [Reference Citation Analysis]
258 Zhou G, Zhao J, Ding X, Pan D, Sun Y, Yang J, Zhao Y. Pathological study of 130 cases of nonalcoholic fatty liver disease based on NASH-CRN system. Front Med China 2007;1:413-7. [PMID: 24573937 DOI: 10.1007/s11684-007-0081-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
259 Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombès A. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49:436-442. [PMID: 19085967 DOI: 10.1002/hep.22665] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 8.8] [Reference Citation Analysis]
260 Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43:509-518. [PMID: 18648737 DOI: 10.1007/s00535-008-2193-6] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 9.2] [Reference Citation Analysis]
261 Keasler VV, Lerat H, Madden CR, Finegold MJ, Mcgarvey MJ, Mohammed EM, Forbes SJ, Lemon SM, Hadsell DL, Grona SJ, Hollinger FB, Slagle BL. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. Virology 2006;347:466-75. [DOI: 10.1016/j.virol.2005.11.050] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
262 Enjoji M, Kohjima M, Kotoh K, Nakamuta M. Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments. Int J Hepatol. 2012;2012:264017. [PMID: 22701799 DOI: 10.1155/2012/264017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
263 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
264 Martin-carbonero L, Soriano V. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. AIDS 2005;19:621-3. [DOI: 10.1097/01.aids.0000163939.08811.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
265 Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, Hotta H, Maekawa Y, Hayashi Y, Kudo M. Correlation between Insulin Resistance and Outcome of Pegylated Interferon and Ribavirin Therapy, Hepatic Steatosis, Hepatic Fibrosis in Chronic Hepatitis C-1b and High Viral Load. Digestion 2011;84:5-9. [DOI: 10.1159/000333208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
266 Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. 2005;41:809-818. [PMID: 15793848 DOI: 10.1002/hep.20650] [Cited by in Crossref: 249] [Cited by in F6Publishing: 247] [Article Influence: 15.6] [Reference Citation Analysis]
267 Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA. Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study. PLoS One 2017;12:e0173125. [PMID: 28264004 DOI: 10.1371/journal.pone.0173125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Iwasa M, Hara N, Miyachi H, Tanaka H, Takeo M, Fujita N, Kobayashi Y, Kojima Y, Kaito M, Takei Y. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. J Viral Hepat. 2009;16:716-723. [PMID: 19302338 DOI: 10.1111/j.1365-2893.2009.01119.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
269 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepat Mon 2012;12:77-84. [PMID: 22509183 DOI: 10.5812/hepatmon.829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
270 Miquilena Colina ME, García Monzón C. [Obesity and liver disease]. Gastroenterol Hepatol 2010;33:591-604. [PMID: 20206411 DOI: 10.1016/j.gastrohep.2009.12.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Cross TJ, Quaglia A, Nolan J, Hughes S, Harrison PM. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection? J Med Virol 2010;82:958-64. [PMID: 20419809 DOI: 10.1002/jmv.21744] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
272 Krssák M, Hofer H, Wrba F, Meyerspeer M, Brehm A, Lohninger A, Steindl-Munda P, Moser E, Ferenci P, Roden M. Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. Eur J Radiol. 2010;74:e60-e66. [PMID: 19406596 DOI: 10.1016/j.ejrad.2009.03.062] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
273 Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008;14:1287-1293. [PMID: 18756451 DOI: 10.1002/lt.21524] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 7.3] [Reference Citation Analysis]
274 Himoto T, Yoneyama H, Kurokohchi K, Inukai M, Masugata H, Goda F, Haba R, Watababe S, Kubota S, Senda S, Masaki T. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. Nutr Res 2011;31:829-35. [PMID: 22118753 DOI: 10.1016/j.nutres.2011.09.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
275 Babudieri S, Soddu A, Nieddu P, Tanca A, Madeddu G, Addis M, Pagnozzi D, Cossu-rocca P, Massarelli G, Dore M, Uzzau S, Mura M. Proteomic characterization of hepatitis C eradication: Enzyme switch in the healing liver. Journal of Clinical Virology 2013;57:274-8. [DOI: 10.1016/j.jcv.2013.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
276 Björnsson E, Angulo P. Hepatitis C and steatosis. Arch Med Res. 2007;38:621-627. [PMID: 17613353 DOI: 10.1016/j.arcmed.2006.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
277 Hsu C, Liu C, Liu C, Hsu S, Chen C, Hwang J, Lai M, Chen P, Chen D, Kao J. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection: Metabolic profiles and hepatic fibrosis. Journal of Gastroenterology and Hepatology 2010;25:970-7. [DOI: 10.1111/j.1440-1746.2009.06186.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
278 Lapumnuaypol K, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis. Hosp Pract (1995). 2019;47:105-110. [PMID: 31018721 DOI: 10.1080/21548331.2019.1612066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
279 Lonardo A, Bagni A, Tarugi P, Loria P. The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. Eur J Gastroenterol Hepatol. 2004;16:1043-1050. [PMID: 15371930 DOI: 10.1097/00042737-200410000-00015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
280 Alaei M, Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes & Metabolism 2008;34:692-700. [DOI: 10.1016/s1262-3636(08)74606-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
281 Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005;100:616-623. [PMID: 15743360 DOI: 10.1111/j.1572-0241.2005.41289.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 8.8] [Reference Citation Analysis]
282 Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, Hadziyannis E, Pandelidaki H, Zafiropoulou R, Savvas S. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol. 2007;102:634-641. [PMID: 17222326 DOI: 10.1111/j.1572-0241.2006.01025.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
283 Forman LM. Metabolic syndrome in liver transplantation: The elephant in the room. Liver Transpl 2008;14:1245-8. [DOI: 10.1002/lt.21591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
284 Blackett PR, Wilson DP, McNeal CJ. Secondary hypertriglyceridemia in children and adolescents. J Clin Lipidol 2015;9:S29-40. [PMID: 26343210 DOI: 10.1016/j.jacl.2015.04.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
285 Persico M, Masarone M, Mura VL, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. World J Gastroenterol 2009; 15(4): 462-466 [PMID: 19152451 DOI: 10.3748/wjg.15.462] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
286 Bellan M, Rigamonti C, Giacomini GM, Makmur G, Marconi C, Nicosia F, Panero A, De Benedittis C, Burlone ME, Minisini R, Pirisi M. Liver Stiffness, Not Fat Liver Content, Predicts the Length of QTc Interval in Patients with Chronic Liver Disease. Gastroenterol Res Pract 2019;2019:6731498. [PMID: 31933631 DOI: 10.1155/2019/6731498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
287 Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. Hepatol Int 2013;7 Suppl 2:782-9. [PMID: 24587848 DOI: 10.1007/s12072-013-9460-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
288 Rembeck K, Maglio C, Lagging M, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Norkrans G. PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Med Genet. 2012;13:82. [PMID: 22978414 DOI: 10.1186/1471-2350-13-82] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
289 Kaibori M, Ishizaki M, Iida H, Matsui K, Sakaguchi T, Inoue K, Mizuta T, Ide Y, Iwasaka J, Kimura Y, Hayashi F, Habu D, Kon M. Effect of Intramuscular Adipose Tissue Content on Prognosis in Patients Undergoing Hepatocellular Carcinoma Resection. J Gastrointest Surg 2015;19:1315-23. [DOI: 10.1007/s11605-015-2838-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
290 Czaja MJ. Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 2011;140:1895-908. [PMID: 21530520 DOI: 10.1053/j.gastro.2011.04.038] [Cited by in Crossref: 119] [Cited by in F6Publishing: 113] [Article Influence: 11.9] [Reference Citation Analysis]
291 Delgado-Borrego A, Kamegaya Y, Jordan SH, Agrawal S, Valim C, Chung RT. HCV synergizes with body weight in the promotion of insulin resistance. J Viral Hepat 2011;18:135-41. [PMID: 20497310 DOI: 10.1111/j.1365-2893.2010.01291.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
292 Pujol FH, Devesa M. Genotypic variability of hepatitis viruses associated with chronic infection and the development of hepatocellular carcinoma. J Clin Gastroenterol 2005;39:611-8. [PMID: 16000930 DOI: 10.1097/01.mcg.0000170770.49394.92] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
293 Kushner RF. Obesity Management. Gastroenterology Clinics of North America 2007;36:191-210. [DOI: 10.1016/j.gtc.2007.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
294 Unger LW, Forstner B, Schneglberger S, Muckenhuber M, Eigenbauer E, Scheiner B, Mandorfer M, Trauner M, Reiberger T. Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. Wien Klin Wochenschr. 2019;131:395-403. [PMID: 31493100 DOI: 10.1007/s00508-019-01544-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
295 Silva T, Colombo G, Schiavon L. Adiponectin: A multitasking player in the field of liver diseases. Diabetes & Metabolism 2014;40:95-107. [DOI: 10.1016/j.diabet.2013.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
296 Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005;19:585-92. [DOI: 10.1097/01.aids.0000163935.99401.25] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 8.3] [Reference Citation Analysis]
297 Falasca K, Ucciferri C, Mancino P, Vitacolonna E, De Tullio D, Pizzigallo E, Conti P, Vecchiet J. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J Med Virol 2008;80:1900-6. [PMID: 18814247 DOI: 10.1002/jmv.21292] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
298 Loria P, Lonardo A, Carulli N. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004;39:1748-1748. [DOI: 10.1002/hep.20252] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]